Skip to main content
Erschienen in: International Cancer Conference Journal 2/2024

25.01.2024 | Case Report - Complication

Remarkable remission of symptomatic dermatomyositis after curative breast cancer surgery

verfasst von: Makoto Fujino, Masahiro Kawashima, Hajime Yoshifuji, Ran Nakashima, Yosuke Yamada, Yoshiaki Matsumoto, Nobuko Kawaguchi-Sakita, Yukiko Mori, Fengling Pu, Ayane Yamaguchi, Kosuke Kawaguchi, Masahiro Takada, Masakazu Toi

Erschienen in: International Cancer Conference Journal | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Dermatomyositis (DM) is an autoimmune disease that causes proximal muscle weakness in the extremities leading to severe immobility and dysphagia. Approximately 20% of patients with DM are positive for anti-TIF-1γ antibody and frequently accompanied by malignant tumors. Although DM remission after tumor resection has been reported, the indications for surgery in patients with severe DM are unknown. Herein, we report a case of a 79-year-old Japanese woman who presented with breast cancer and anti-TIF-1γ antibody-positive DM. She became bedridden shortly after DM onset. Although pulsed steroid therapy, intravenous immunoglobulin, tacrolimus, and endocrine therapy with fulvestrant did not improve her symptoms, tumor resection with axillary lymph node dissection resulted in complete remission of the DM after 8 months. Immunohistochemistry revealed high expression of TIF-1γ in cancer cells, both in the primary tumor and axillary lymph nodes. Since the serum levels of anti-TIF-1γ antibody decreased after the surgery, the existence of breast cancer with TIF-1γ expression may have contributed to the worsening of DM. The present case suggests that curative surgery should be considered as a treatment option even if the patient has severe symptoms, such as immobility and dysphagia. Careful discussions with patients and multidisciplinary collaboration are essential to make surgery feasible, particularly for those with severe symptomatic DM.
Literatur
1.
Zurück zum Zitat Sandhu NP, Zakaria S, Degnim AC, Boughey JC (2011) Dermatomyositis presenting as a paraneoplastic syndrome due to underlying breast cancer. BMJ Case Rep 2011 Sandhu NP, Zakaria S, Degnim AC, Boughey JC (2011) Dermatomyositis presenting as a paraneoplastic syndrome due to underlying breast cancer. BMJ Case Rep 2011
2.
Zurück zum Zitat Kubeček O, Soukup T, Paulík A, Kopecký J (2016) Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report. BMC Cancer 16(1):684CrossRefPubMedPubMedCentral Kubeček O, Soukup T, Paulík A, Kopecký J (2016) Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report. BMC Cancer 16(1):684CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Piras M, Panebianco M, Garibaldi M, Roberto M, Merlonghi G, Pellegrini P et al (2021) A case of pathological complete response and resolution of dermatomyositis following neoadjuvant chemotherapy in HER2-positive early breast cancer. Curr Oncol 28(3):1957–1961CrossRefPubMedPubMedCentral Piras M, Panebianco M, Garibaldi M, Roberto M, Merlonghi G, Pellegrini P et al (2021) A case of pathological complete response and resolution of dermatomyositis following neoadjuvant chemotherapy in HER2-positive early breast cancer. Curr Oncol 28(3):1957–1961CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Kassem L, Deygas M, Fattet L, Lopez J, Goulvent T, Lavergne E et al (2015) TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients. BMC Cancer 15:453CrossRefPubMedPubMedCentral Kassem L, Deygas M, Fattet L, Lopez J, Goulvent T, Lavergne E et al (2015) TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients. BMC Cancer 15:453CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Blanes M, Bañuls J, Yuste A, Adrover E, Pascual JC, Pastor N et al (2005) Amyopathic dermatomyositis associated with a recurrence of breast cancer. Actas Dermosifiliogr 96(5):299–302CrossRefPubMed Blanes M, Bañuls J, Yuste A, Adrover E, Pascual JC, Pastor N et al (2005) Amyopathic dermatomyositis associated with a recurrence of breast cancer. Actas Dermosifiliogr 96(5):299–302CrossRefPubMed
6.
Zurück zum Zitat Pectasides D, Koumpou M, Gaglia A, Pectasides M, Lambadiari V, Lianos E et al (2006) Dermatomyositis associated with breast cancer. Anticancer Res 26(3b):2329–2331PubMed Pectasides D, Koumpou M, Gaglia A, Pectasides M, Lambadiari V, Lianos E et al (2006) Dermatomyositis associated with breast cancer. Anticancer Res 26(3b):2329–2331PubMed
7.
Zurück zum Zitat Sereda D, Werth VP (2006) Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol 142(1):70–72CrossRefPubMed Sereda D, Werth VP (2006) Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol 142(1):70–72CrossRefPubMed
9.
Zurück zum Zitat Yamashita H, Kobayashi S, Iwase H, Itoh Y, Masaoka A (1994) Recurrent breast cancer at 21 years after resection detected by serum tumor markers and manifested as dermatomyositis. Breast Cancer 1(1):65–68CrossRefPubMed Yamashita H, Kobayashi S, Iwase H, Itoh Y, Masaoka A (1994) Recurrent breast cancer at 21 years after resection detected by serum tumor markers and manifested as dermatomyositis. Breast Cancer 1(1):65–68CrossRefPubMed
10.
Zurück zum Zitat Song YJ, Wu YF, Fan T (2010) Dermatosis as the initial manifestation of malignant breast tumors: retrospective analysis of 4 cases. Breast Care (Basel) 5(3):174–176CrossRefPubMed Song YJ, Wu YF, Fan T (2010) Dermatosis as the initial manifestation of malignant breast tumors: retrospective analysis of 4 cases. Breast Care (Basel) 5(3):174–176CrossRefPubMed
11.
Zurück zum Zitat Kumar N, Deo S (2020) Paraneoplastic dermatomyositis in hereditary breast and ovarian cancer syndrome. Breast J 26(9):1836–1837CrossRefPubMed Kumar N, Deo S (2020) Paraneoplastic dermatomyositis in hereditary breast and ovarian cancer syndrome. Breast J 26(9):1836–1837CrossRefPubMed
12.
Zurück zum Zitat Osako T, Ito Y, Morimatsu A, Tada K, Sakurai N, Takahashi S et al (2007) Flare-up of dermatomyositis along with recurrence of breast cancer. Breast J 13(2):200–202CrossRefPubMed Osako T, Ito Y, Morimatsu A, Tada K, Sakurai N, Takahashi S et al (2007) Flare-up of dermatomyositis along with recurrence of breast cancer. Breast J 13(2):200–202CrossRefPubMed
13.
Zurück zum Zitat Sakai T, Ogura Y, Narita J, Kimura D, Suto T, Ainai S et al (2005) Metachronous bilateral primary breast cancer associated with dermatomyositis. Breast J 11(3):225–226CrossRefPubMed Sakai T, Ogura Y, Narita J, Kimura D, Suto T, Ainai S et al (2005) Metachronous bilateral primary breast cancer associated with dermatomyositis. Breast J 11(3):225–226CrossRefPubMed
15.
Zurück zum Zitat Moghimi M, Khodadadi K (2021) Dermatomyositis following biosimilar trastuzumab in a breast cancer patient: a case report. Case Rep Oncol 14(2):1134–1138CrossRefPubMedPubMedCentral Moghimi M, Khodadadi K (2021) Dermatomyositis following biosimilar trastuzumab in a breast cancer patient: a case report. Case Rep Oncol 14(2):1134–1138CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Allouch A, Zaatarikahale TB, Moussa MK, Jounblat Y, Bitar N (2020) Dermatomyositis: a presenting clinical vignette in a patient with breast cancer. Cureus 12(9):e10624PubMedPubMedCentral Allouch A, Zaatarikahale TB, Moussa MK, Jounblat Y, Bitar N (2020) Dermatomyositis: a presenting clinical vignette in a patient with breast cancer. Cureus 12(9):e10624PubMedPubMedCentral
17.
Zurück zum Zitat Hendren E, Vinik O, Faragalla H, Haq R (2017) Breast cancer and dermatomyositis: a case study and literature review. Curr Oncol 24(5):e429–e433CrossRefPubMedPubMedCentral Hendren E, Vinik O, Faragalla H, Haq R (2017) Breast cancer and dermatomyositis: a case study and literature review. Curr Oncol 24(5):e429–e433CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Pellegrino B, Mazzaschi G, Madeddu D, Mori C, Lagrasta CAM, Missale G et al (2020) Clinico-immunological profile of a 67-year-old woman affected by HER2-positive breast cancer and autoimmune dermatomyositis. Front Oncol 10:192CrossRefPubMedPubMedCentral Pellegrino B, Mazzaschi G, Madeddu D, Mori C, Lagrasta CAM, Missale G et al (2020) Clinico-immunological profile of a 67-year-old woman affected by HER2-positive breast cancer and autoimmune dermatomyositis. Front Oncol 10:192CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Goto W, Kashiwagi S, Asano Y, Takada K, Morisaki T, Noda S et al (2017) A case of breast cancer associated with dermatitis that was difficult to differentiate from dermatomyositis. Gan To Kagaku Ryoho 44(12):1930–1932PubMed Goto W, Kashiwagi S, Asano Y, Takada K, Morisaki T, Noda S et al (2017) A case of breast cancer associated with dermatitis that was difficult to differentiate from dermatomyositis. Gan To Kagaku Ryoho 44(12):1930–1932PubMed
20.
Zurück zum Zitat Voravud N, Dimopoulos M, Hortobagyi G, Ross M, Theriault R (1991) Breast cancer and second primary ovarian cancer in dermatomyositis. Gynecol Oncol 43(3):286–290CrossRefPubMed Voravud N, Dimopoulos M, Hortobagyi G, Ross M, Theriault R (1991) Breast cancer and second primary ovarian cancer in dermatomyositis. Gynecol Oncol 43(3):286–290CrossRefPubMed
21.
Zurück zum Zitat Cai Y, Qiao J, Fang H (2012) Metachronous multiple primary malignant neoplasms in a patient with dermatomyositis. Indian J Dermatol Venereol Leprol 78(5):665CrossRefPubMed Cai Y, Qiao J, Fang H (2012) Metachronous multiple primary malignant neoplasms in a patient with dermatomyositis. Indian J Dermatol Venereol Leprol 78(5):665CrossRefPubMed
22.
Zurück zum Zitat Kikuchi N, Ohashi T, Miura T, Nishibu A, Yamamoto T (2017) Triple cancers concurrently detected in a case of antitranscriptional intermediary factor-1γ antibody-positive dermatomyositis. Int J Dermatol 56(12):1516–1517CrossRefPubMed Kikuchi N, Ohashi T, Miura T, Nishibu A, Yamamoto T (2017) Triple cancers concurrently detected in a case of antitranscriptional intermediary factor-1γ antibody-positive dermatomyositis. Int J Dermatol 56(12):1516–1517CrossRefPubMed
23.
Zurück zum Zitat Otsuka Y, Watanabe H, Kano Y, Tatebe N, Sunahori-Watanabe K, Kawabata T et al (2017) Occurrence of dermatomyositis immediately after mastectomy subsequent to severe chemotherapeutic drug eruption. Intern Med 56(24):3379–3383CrossRefPubMedPubMedCentral Otsuka Y, Watanabe H, Kano Y, Tatebe N, Sunahori-Watanabe K, Kawabata T et al (2017) Occurrence of dermatomyositis immediately after mastectomy subsequent to severe chemotherapeutic drug eruption. Intern Med 56(24):3379–3383CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Goyal S, Nousari HC (1999) Paraneoplastic amyopathic dermatomyositis associated with breast cancer recurrence. J Am Acad Dermatol 41(5 Pt 2):874–875CrossRefPubMed Goyal S, Nousari HC (1999) Paraneoplastic amyopathic dermatomyositis associated with breast cancer recurrence. J Am Acad Dermatol 41(5 Pt 2):874–875CrossRefPubMed
25.
Zurück zum Zitat Kim Y, Jung W, Park YH (2015) Dermatomyositis and paclitaxel-induced cutaneous drug eruption associated with metastatic breast cancer. J Breast Cancer 18(2):195–199CrossRefPubMedPubMedCentral Kim Y, Jung W, Park YH (2015) Dermatomyositis and paclitaxel-induced cutaneous drug eruption associated with metastatic breast cancer. J Breast Cancer 18(2):195–199CrossRefPubMedPubMedCentral
26.
27.
Zurück zum Zitat Ahuja S, Makkar P, Gupta S, Vigoda I (2016) Paraneoplastic syndrome and underlying breast cancer: a worsening rash despite initiation of chemotherapy. J Community Support Oncol 14(5):229–231CrossRefPubMed Ahuja S, Makkar P, Gupta S, Vigoda I (2016) Paraneoplastic syndrome and underlying breast cancer: a worsening rash despite initiation of chemotherapy. J Community Support Oncol 14(5):229–231CrossRefPubMed
28.
Zurück zum Zitat Matsushita T, Takehara K, Oishi K, Maeda S, Hamaguchi Y, Ishikawa S et al (2017) Case of anti-transcriptional intermediary factor-1-positive dermatomyositis associated with breast cancer developing over 10 years. J Dermatol 44(8):972–973CrossRefPubMed Matsushita T, Takehara K, Oishi K, Maeda S, Hamaguchi Y, Ishikawa S et al (2017) Case of anti-transcriptional intermediary factor-1-positive dermatomyositis associated with breast cancer developing over 10 years. J Dermatol 44(8):972–973CrossRefPubMed
29.
Zurück zum Zitat Ogawa M, Sugiura K, Yokota K, Muro Y, Akiyama M (2016) Anti-transcription intermediary factor 1-γ antibody-positive clinically amyopathic dermatomyositis complicated by interstitial lung disease and breast cancer. J Eur Acad Dermatol Venereol 30(2):373–375CrossRefPubMed Ogawa M, Sugiura K, Yokota K, Muro Y, Akiyama M (2016) Anti-transcription intermediary factor 1-γ antibody-positive clinically amyopathic dermatomyositis complicated by interstitial lung disease and breast cancer. J Eur Acad Dermatol Venereol 30(2):373–375CrossRefPubMed
30.
Zurück zum Zitat Primiano G, Plantone D, Sauchelli D, Cuccagna C, Renna R, Iorio R et al (2012) Resolution of muscle inflammation after tumor removal in a woman with paraneoplastic dermatomyositis. J Rheumatol 39(12):2359–2360CrossRefPubMed Primiano G, Plantone D, Sauchelli D, Cuccagna C, Renna R, Iorio R et al (2012) Resolution of muscle inflammation after tumor removal in a woman with paraneoplastic dermatomyositis. J Rheumatol 39(12):2359–2360CrossRefPubMed
31.
Zurück zum Zitat Luu X, Leonard S, Joseph KA (2015) Dermatomyositis presenting as a paraneoplastic syndrome with resolution of symptoms following surgical management of underlying breast malignancy. J Surg Case Rep 2015(7):rjv075CrossRefPubMedPubMedCentral Luu X, Leonard S, Joseph KA (2015) Dermatomyositis presenting as a paraneoplastic syndrome with resolution of symptoms following surgical management of underlying breast malignancy. J Surg Case Rep 2015(7):rjv075CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Khoo HY, Tan WJ, Cheong YT (2018) Breast cancer with dermatomyositis as initial presentation. Med J Malaysia 73(1):44–45PubMed Khoo HY, Tan WJ, Cheong YT (2018) Breast cancer with dermatomyositis as initial presentation. Med J Malaysia 73(1):44–45PubMed
33.
Zurück zum Zitat Yesmin S, Sanyal M, Hasan MJ (2019) Breast cancer with paraneoplastic syndrome in a 72 year old male patient. Mymensingh Med J 28(1):254–258PubMed Yesmin S, Sanyal M, Hasan MJ (2019) Breast cancer with paraneoplastic syndrome in a 72 year old male patient. Mymensingh Med J 28(1):254–258PubMed
34.
Zurück zum Zitat Zhang L, Zhang C, Yang Z, He M, Zhang L, Ezzat S et al (2017) Male occult triple-negative breast cancer with dermatomyositis: a case report and review of the literature. Onco Targets Ther 10:5459–5462CrossRefPubMedPubMedCentral Zhang L, Zhang C, Yang Z, He M, Zhang L, Ezzat S et al (2017) Male occult triple-negative breast cancer with dermatomyositis: a case report and review of the literature. Onco Targets Ther 10:5459–5462CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Biyi A, Doudouh A (2016) Muscular visualisation on a bone scan in paraneoplastic dermatomyositis associated with breast cancer. Pan Afr Med J 23:9CrossRefPubMedPubMedCentral Biyi A, Doudouh A (2016) Muscular visualisation on a bone scan in paraneoplastic dermatomyositis associated with breast cancer. Pan Afr Med J 23:9CrossRefPubMedPubMedCentral
36.
37.
Zurück zum Zitat Vaccaro M, Borgia F, Barbuzza O, Gangemi S, Guarneri B (2010) Dermatomyositis and cutaneous metastases from breast cancer: simultaneous development and parallel course. Rheumatol Int 30(8):1091–1093CrossRefPubMed Vaccaro M, Borgia F, Barbuzza O, Gangemi S, Guarneri B (2010) Dermatomyositis and cutaneous metastases from breast cancer: simultaneous development and parallel course. Rheumatol Int 30(8):1091–1093CrossRefPubMed
38.
Zurück zum Zitat Inaguma G, Shimada A, Tsunoda J, Matsuzaki T, Nishi T, Seki H et al (2020) Inflammatory breast cancer associated with amyopathic dermatomyositis: a case report. Surg Case Rep 6(1):284CrossRefPubMedPubMedCentral Inaguma G, Shimada A, Tsunoda J, Matsuzaki T, Nishi T, Seki H et al (2020) Inflammatory breast cancer associated with amyopathic dermatomyositis: a case report. Surg Case Rep 6(1):284CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Dias LP, Faria AL, Scandiuzzi MM, Inhaia CL, Shida JY, Gebrim LH (2015) A rare case of severe myositis as paraneoplastic syndrome on breast cancer. World J Surg Oncol 13:134CrossRefPubMedPubMedCentral Dias LP, Faria AL, Scandiuzzi MM, Inhaia CL, Shida JY, Gebrim LH (2015) A rare case of severe myositis as paraneoplastic syndrome on breast cancer. World J Surg Oncol 13:134CrossRefPubMedPubMedCentral
Metadaten
Titel
Remarkable remission of symptomatic dermatomyositis after curative breast cancer surgery
verfasst von
Makoto Fujino
Masahiro Kawashima
Hajime Yoshifuji
Ran Nakashima
Yosuke Yamada
Yoshiaki Matsumoto
Nobuko Kawaguchi-Sakita
Yukiko Mori
Fengling Pu
Ayane Yamaguchi
Kosuke Kawaguchi
Masahiro Takada
Masakazu Toi
Publikationsdatum
25.01.2024
Verlag
Springer Nature Singapore
Erschienen in
International Cancer Conference Journal / Ausgabe 2/2024
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-023-00646-2

Weitere Artikel der Ausgabe 2/2024

International Cancer Conference Journal 2/2024 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.